Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,558 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05038150RecruitingPhase 1/Phase 2
Early-stage drug study for advanced cancers that stopped responding
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
Gilbert, ArizonaAges 18–75 - NCT04740398RecruitingPhase 1
CBP-1008 for advanced solid tumors that standard therapy failed
This Phase 1 study tests CBP-1008, a new experimental treatment, in people with advanced solid cancers that either worsened after standard treatment or for which no standard option exists. It may help doctors learn the safest dose and whether it shows signs of benefit in specific tumor types.
Beijing, Beijing MunicipalityAges 18–70 - NCT05103345RecruitingPhase 1/Phase 2
Injection into tumors to treat advanced solid cancers
This early-phase study tests a medicine called SGN1 given directly into a solid tumor. It’s for people with advanced cancers that have not responded to standard treatment (or don’t have good standard options) and aims to see if the injection is safe and may work.
Guangzhou, GuangdongAges 18–75 - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05142423RecruitingPhase 1/Phase 2
First study of AK109 plus AK104 for advanced solid cancers
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT05547321RecruitingPhase 1
New cancer drug plus immunotherapy for advanced solid tumors
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Boston, MassachusettsAges 18 years+ - NCT04093466RecruitingPhase 1
Testing a new pill for advanced solid tumors
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+ - NCT05645276RecruitingPhase 1
Study of AK129 for advanced solid tumors
This Phase 1 study tests AK129 in people with advanced cancers that have spread. It looks for a safe dose and early signs the treatment may work, especially for tumors with measurable disease and needed prior treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06257680RecruitingPhase 1
ReT01 cell therapy for advanced solid tumors
This trial tests a new cell therapy called ReT01 for people with advanced solid tumors that have stopped responding to standard treatments. It uses your own immune cells from a tumor sample to fight the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06167317RecruitingPhase 1
Study of GS-0201 alone and combined for advanced solid tumors
This trial tests a new drug called GS-0201, either by itself or with other treatments, for people with advanced solid tumors. The goal is to see if it is safe and helpful.
Boston, MassachusettsAges 18 years+ - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06035679Recruiting
Combination therapy before surgery for HER2-positive breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for HER2-positive breast cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT07126665RecruitingPhase 1/Phase 2
Study of MHB088C plus MHB039A for advanced solid tumors
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT06454864Recruiting
Exercise and Diet for Breast Cancer Survivors
This study tests whether a 6-month program combining weekly supervised exercise and dietary advice can improve health in breast cancer survivors who have completed initial treatments. It aims to help with weight, heart health, and overall well-being.
Toronto, OntarioAges Any age - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT07669415RecruitingPhase 2
LM-168 combined with other treatments for advanced solid tumors
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06434597RecruitingPhase 2
Study of SPH5030 for HER2-positive advanced colorectal or bile duct cancer
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
BeijingAges 18 years+ - NCT06417554RecruitingPhase 1/Phase 2
Study of SHR-A2102 with or without other cancer drugs for advanced solid tumors
This trial tests a new drug, SHR-A2102, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy or for those who have not yet received systemic treatment. The goal is to see if it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06877650RecruitingPhase 1/Phase 2
Study of JMT108 for advanced solid tumors
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,558 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.